EUVIMEDEUVIMED entdecken
Leserbrief

A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study

Hailong Tang iD, Weijing Jia, Shuangshuang Jia iD, Runan Dong, Shan Gao, Juan Feng, Hongjuan Dong, Hongtao Gu, Tao Zhang, Ruifeng Yuan, Xiangxiang Liu, Lu Cheng und 2 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27289 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Hailong Tang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Sulfonamides, Dexamethasone, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 6 Literaturangaben. Gefördert von: Translational Project of National Medical Center, Clinical New Technology Application Innovation Project of the Fourth Military Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesDexamethasoneBridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansMaleFemaleProspective StudiesMiddle AgedAdultAgedTreatment Outcome

Substanzen

SulfonamidesDexamethasoneBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Department of Hematology, Weinan Central Hospital, Weinan, China.

ORCID-Profile: Hailong Tang, Shuangshuang Jia, Guangxun Gao

Förderung

  • Translational Project of National Medical Center
  • Clinical New Technology Application Innovation Project of the Fourth Military Medical University
  • National Natural Science Foundation of China
  • Health Scientific Research Innovation Ability Improvement Project of Shaanxi Province
  • Social Development Key Project of Shaanxi Province

Zitieren

APA

Tang, H., Jia, W., Jia, S., Dong, R., Gao, S., Feng, J., Dong, H., Gu, H., Zhang, T., Yuan, R., Liu, X., Cheng, L., Zhou, S., & Gao, G. (2024). A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study. American Journal of Hematology. https://doi.org/10.1002/ajh.27289

Vancouver

Tang H, Jia W, Jia S, Dong R, Gao S, Feng J, et al. A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study. American Journal of Hematology. 2024. doi:10.1002/ajh.27289

BibTeX
@article{Tang2024,
  author = {Tang, Hailong and Jia, Weijing and Jia, Shuangshuang and Dong, Runan and Gao, Shan and Feng, Juan and Dong, Hongjuan and Gu, Hongtao and Zhang, Tao and Yuan, Ruifeng and Liu, Xiangxiang and Cheng, Lu and Zhou, Shuya and Gao, Guangxun},
  title = {A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27289}
}
Kostenlos starten →